Search Results
Your search for BILL matches 305 pages
Showing 151 - 200For HPV Vaccine to Have Optimal Impact, ‘Provider Hesitancy’ Must Be Overcome
Honoring National Cancer Institute researchers Douglas R. Lowy, MD, and John T. Schiller, PhD, with the Lasker-DeBakey Clinical Medical Research Award for advances in technology that enabled the development of human papillomavirus (HPV) vaccines to prevent cervical cancer and other tumors caused by ...
With Financial Toxicity in Oncology Care on the Rise, Providers Need to Help Address Patients’ Financial Issues
At the 2017 ASCO Quality Care Symposium, Dan Sherman, MA, LPC, discussed potential solutions to the persistent challenge of financial toxicity in the oncology setting. Mr. Sherman is a clinical financial consultant and Founder and President of The Navectis Group, Caledonia, Michigan. Rather than...
Second Annual ASCO Advocacy Summit Convenes in Washington, DC
Nearly 100 oncology care providers from across the United States traveled to Capitol Hill on September 27 and 28 to participate in the second annual ASCO Advocacy Summit. Advocates met with Members of Congress and their staff to educate them on critical issues affecting patients with cancer ...
Maintaining Predictable Increases in NIH Funding for Cancer Research
CONGRESS RECENTLY passed its fiscal year (FY) 2017 spending bill, which contains an additional $2 billion for the National Institutes of Health (NIH). This marks the first time in more than a dozen years that Congress funded back-to-back increases for the NIH, demonstrating the bipartisan...
Pioneer in Geriatric Oncology, Hyman Muss, MD, Continues to Improve Care for Older Patients
Hyman Muss, MD, a pioneer in geriatric oncology, considers himself “a real Brooklyn boy.” His father was a dentist, and his uncle was a general practitioner. “They both practiced out of a small brownstone house in Brownsville-Crown Heights. It was sort of reminiscent of the famous movie The Last...
Six NY Scientists Win Pershing Square Sohn Prize for Young Investigators in Cancer Research
The Pershing Square Sohn Cancer Research Alliance announced the six winners of the 4th annual Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to promising early-career, New York City–area scientists. Recipients receive $200,000 in funding per year for up...
Texas Medical Center Names William F. McKeon President and CEO
The Texas Medical Center (TMC) has announced that its Board of Directors has appointed William F. McKeon as President and Chief Executive Officer (CEO) and member of the Board of Directors. Mr. McKeon previously held the position of Executive Vice President, Chief Strategy and Operating Officer....
Ensuring Equitable Cancer Care for All Patients
Cancer is the second-leading cause of death across the globe. Significant efforts, such as the National Cancer Moonshot Initiative and The University of Texas MD Anderson Cancer Center’s Moon Shots Program, will drive advances in cancer prevention, screening, and treatment. However, right now,...
A New Book Deals With an Age-Old Crisis: Cancer Patients and Mortality
The field of psycho-oncology began to take hold in the mid-1970s, when the “C” word was beginning to lose its long-held stigmatization, and patients with cancer could finally begin to openly reveal their diagnosis and express their feelings about their life-threatening disease. Despite that social ...
AMA Statement on House Passage of American Health Care Act
American Medical Association (AMA) President Andrew W. Gurman, MD, released the following statement today after the U.S. House of Representatives passed the American Health Care Act: “The bill passed by the House today will result in millions of Americans losing access to quality,...
ASCO Applauds Congress for Providing Additional $2 Billion in NIH Funding
On May 1, Congress announced a bipartisan 2017 budget deal that contains a $2 billion increase in medical research funding for the National Institutes of Health (NIH), including $475 million more for the National Cancer Institute. The budget also maintains funding for cancer control programs at the ...
ASCO Addresses New Policies That Threaten Access to Opioids
Since the mid-2000s, medication and illicit drug abuse in the United Sates has steadily increased, creating what has now been termed an “opioid epidemic.” In response, Congress and the Bush and Obama Administrations have launched intervention and regulatory proposals to help turn the troubling...
Make Vaccination Great Again
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. It affects 80% of individuals, with the initial infection usually occurring between the ages of 15 and 24. Persistent infection with oncogenic HPV genotypes, primarily 16 and 18, is the cause of virtually all...
Exploring the Opportunities and Challenges of Seamless Drug Development
The traditional three-phase clinical trial process for testing new drugs does not necessarily make sense when it comes to targeted therapies, according to many experts, including regulators, academic researchers, industry chief executive officers, and patient advocates alike. Instead of three...
Exploring the Opportunities and Challenges of Seamless Drug Development
The traditional three-phase clinical trial process for testing new drugs does not necessarily make sense when it comes to targeted therapies, according to many experts, including regulators, academic researchers, industry chief executive officers, and patient advocates alike. Instead of three...
Timing Is Everything
In 1959, my 5-year-old cousin, Kim, was diagnosed with acute lymphocytic leukemia (ALL). As an 8-year-old, I didn’t really understand what was happening to him, except that he had to go to the Riley Hospital for Children in Indianapolis, Indiana, for treatment. The haunting vision of his looking...
Has the Affordable Care Act Reduced Socioeconomic Disparities in Cancer Screening?
Out-of-pocket expenditures are thought to be a significant barrier to receiving cancer preventive services, especially for individuals of lower socioeconomic status. A new study published by Cooper et al in Cancer looked at how the Affordable Care Act (ACA), which eliminated such out-of-pocket...
Oncology Organizations Applaud Passage of the 21st Century Cures Act
On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony ...
Statement From the American Association for Cancer Research on the House Passage of the 21st Century Cures Act
From Nancy E. Davidson, MD, President of the AACR and Executive Director of the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, and Margaret Foti, PhD, MD (hc), Chief Executive Officer of the AACR On behalf of the American Association for Cancer Research (AACR),...
William Sellers, MD, Appointed to Faculty at Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School
William Sellers, MD, a widely respected cancer researcher with extensive experience in cancer genomics and therapeutic discovery, is returning to the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard, Dana-Farber Cancer Institute, and Harvard Medical School (HMS) as a...
ASCO Praises Congress for Accelerating the Development and Delivery of Cancer Treatment With 21st Century Cures Act
In a statement released December 7, ASCO President Daniel F. Hayes, MD, FACP, FASCO, said, “ASCO applauds the U.S. Senate for their decisive vote today to pass the 21st Century Cures Act and authorize funding for the Beau Biden Cancer Moonshot and National Institutes of Health Innovation ...
Elisabeth Heath, MD, FACP, Honored With 2016 Michigan Cancer Consortium Champion Award
Elisabeth Heath, MD, FACP, Leader of the Genitourinary Oncology Multidisciplinary Team and the Patricia C. and E. Jan Hartmann Endowed Chair for Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute, was recently honored with the Michigan Cancer Consortium’s inaugural Champion...
Michael O’Connell, MD, Receives the 2016 ACCC Clinical Research Award
Michael O’Connell, MD, received the Association of Community Cancer Centers (ACCC) 2016 Clinical Research Award in recognition of the significant and positive impact of his research on the oncology patient, family, and the community. ACCC President Jennie R. Crews, MD, MMM, FACP, accepted the...
My Catch-22 Predicament
In the spring of 2011, I was feeling so fatigued I needed to rest after walking just a few steps to the kitchen and not doing anything more strenuous than making a cup of coffee. Fortunately, I have a wonderful primary care physician who takes me seriously when I have a complaint about my health,...
Salk Institute’s Clodagh O’Shea, PhD, Named Howard Hughes Medical Institute Faculty Scholar
Clodagh O’Shea, PhD, Associate Professor in the Salk Institute’s Molecular and Cell Biology Laboratory, is among the first recipients of a grant from the Faculty Scholars Program, a new partnership of Howard Hughes Medical Institute (HHMI), the Bill and Melinda Gates Foundation, and the Simons...
AACR’s Cancer Progress Report Hails Research Advances and Details Challenges Ahead
Although research advances in more effective therapies and diagnostics and improved screening technology over the past 2 decades have led to a 23% reduction in the cancer death rate in the United States, saving nearly 2 million lives,1 cancer remains the second leading cause of death after heart...
Surgery and Radiation ProtecT Against Progression/Metastasis vs Active Monitoring in Prostate Cancer, but at What Cost?
The ProtecT trial showing similar 10-year survival with active monitoring, surgery, or radiotherapy for prostate-specific antigen (PSA)-detected localized prostate cancer but a greater risk of disease progression/metastasis with monitoring was recently reported by Hamdy and colleagues and is...
Risk of Metastasis With Active Monitoring in PSA-Detected Localized Prostate Cancer: The ProtectT Trial
The ProtecT study findings1 are provocative. Despite having a control arm of active monitoring with serial prostate-specific antigen (PSA) testing, as compared with watchful waiting in the prior randomized trials (ie, SPCG-42 and PIVOT3), and also enrolling men with more favorable-risk disease...
American Association for Cancer Research Releases 2016 Cancer Progress Report
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug...
Addressing the Significant Disparities and Barriers to Health Care Experienced by LGBT Cancer Survivors
In 2011, the Institute of Medicine (IOM) published its landmark report “The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding,” which recognized the scarcity of research in lesbian, gay, bisexual, and transgender (LGBT) individuals and the...
Safety Concerns Weigh Heavily in Elderly Patients With Cancer
Active pharmacovigilance in detecting and assessing the safety signals related to drugs and devices, and disseminating those findings to relevant stakeholders, is an important component in delivering safe, high-quality care in the cancer setting. To reach a better understanding of this issue,...
In Memoriam
The ASCO Post remembers the following specialists in oncology who passed away in 2015–2016. Please write to editor@ASCOPost.com to recognize and pay tribute to others in a future issue. Mark R. Green, MD January 3, 1945–February 23, 2015 “Few people have impacted cancer clinical research in the...
Lisa A. Newman, MD, MPH, FACS, FASCO, Balances Her Passions of Surgical Breast Oncology and Breast Cancer Disparity Research, Both Home and Abroad
Lisa A. Newman, MD, MPH, FACS, FASCO, Director of the Henry Ford Health System’s Breast Oncology Program, was born in New York, New York and, according to her, was blessed to have had parents who lived the African American version of the “American Dream.” Dr. Newman’s father was the son of...
ASCO Past-President Anticipates a New Position With an Ongoing Goal of Advancing the Field of Oncology
After an extensive national search, Hartford HealthCare has appointed ASCO Past-President Peter Paul Yu, MD, FACP, FASCO, as the first Physician-in-Chief of the Hartford HealthCare Cancer Institute. As Physician-in-Chief, Dr. Yu will be responsible for working closely and collaboratively with...
Expect Questions About the New Rule on E-Cigarettes
“There are a lot of myths around new and emerging tobacco products, including e-cigarettes, and unfortunately, the biggest misconception is that these products are fairly or entirely harmless and risk-free,” Alexander V. Prokhorov, MD, PhD, said in an interview with The ASCO Post about a new...
New FDA Rule Prohibits Sale of E-Cigarettes to Anyone Under Age 18 and Requires Warning Labels
A new rule extending U.S. Food and Drug Administration (FDA) oversight to all tobacco products, including electronic cigarettes (e-cigarettes), and banning the sale of these products to anyone under the age of 181 was hailed as a major advanced by many leaders of medical and health organizations....
Oncology and Diplomacy in the Middle East
The Middle East is a vast region comprised largely of developing nations with complicated sociopolitical challenges, violent internecine disputes, and deeply fragmented health-care systems. Not surprisingly, the region’s suboptimal health care contributes to the late diagnosis and poor survival...
Raising Awareness of Medullary Thyroid Carcinoma
I’m used to having bumps and cysts pop up on my body, so when I felt a lump on the front of my throat, just below my Adam’s apple, I brushed it off. But when it was still there 6 months later, I became concerned and decided to see an ear, nose, and throat specialist. He performed a fine-needle...
Drug Prices and Value: Finding Middle Ground
The advent of targeted therapies along with complex personalized treatment regimens has added many effective tools to the oncology armamentarium. But progress has a price tag. Although the oncology community needs new drugs, there is growing concern that the price of many newer compounds is...
Computer-Assisted Decision Support in Medical Oncology: We Need It Now
Today’s medical oncologist is increasingly challenged to stay current with the latest developments in cancer treatment. I have been fortunate to speak with many oncologists over the past quarter-century on how professional life has evolved since the 1990s. These conversations have left me with a...
Throwing Out the Baby With the Bathwater: A Critical Appraisal of the USPSTF Recommendation Against Screening for Prostate Cancer
In 2012, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation against routine screening for prostate cancer.1,2 The grade D recommendation was considered controversial at the time, and remains so now, because many stakeholders have weighed the same body of evidence and come to...
An Increase for the National Institutes of Health Budget
The National Institutes of Health (NIH) received a nearly $2 billion funding increase—the first large increase for the agency in more than 12 years—in the federal omnibus spending bill Congress passed on December 18, 2015. And President Barack Obama signed the bill into law a day later. The 6.6%...
ASCO Announces New Award Recognizing Extraordinary Contributions to Cancer Survivorship Care
ASCO has announced the creation of the Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care, intended to recognize and promote the work of pioneers and leaders in the growing field of survivorship. The first award will be presented at the 2017 Cancer Survivorship...
Robert W. Carlson, MD, and William J. Gradishar, MD, on Optimizing Treatment of HER2-Positive Breast Cancer
Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of the breast cancer guidelines, the inclusion of varied fields––such as plastic...
Nationally Regarded Cancer Advocate Ellen Stovall Dies
Passion is a much-needed virtue in one who seeks to change the world for the better. When you combine intelligence, stamina, iron-willed determination, the grace of an ambassador, and simple human likability with passion, you get that rare person who can turn words and ideas into reality. Such a...
Survivorship Symposium 2016: ASCO Announces New Award Recognizing Extraordinary Contributions to Cancer Survivorship Care
ASCO has announced the creation of the Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care, intended to recognize and promote the work of pioneers and leaders in the growing field of survivorship. The first award will be presented at the 2017 Cancer Survivorship...
Death Rates Significantly Reduced for Men Having Radical Prostatectomy vs Watchful Waiting
Estimated 15-year results from the Scandinavian Prostate Cancer Group Study (SPCG-4) show that men diagnosed with early prostate cancer and randomly assigned to radical prostatectomy continued to have significantly reduced rates of death from prostate cancer, death from any cause, and risk of...
Fixing the Drug Shortage: It’s About Time
I have spent the past 30 years trying to improve the results of treatment for advanced cancer. I had the privilege of working with Sir Michael Peckham when the late Professor Tim McElwain and he were evolving variants of the PVB (cisplatin, vinblastine, bleomycin) and PEB (cisplatin, etoposide,...
Increased Use of Hospital Services Boosts Oncology Spending
For our ongoing series on the rising costs of cancer care, The ASCO Post spoke with Lee N. Newcomer, MD, Senior Vice President of Oncology for UnitedHealthcare. Dr. Newcomer is responsible for improving cost-effective cancer care at the nation’s largest health insurer. He shed light on areas of...
Oncology Drug Shortage: An Unintended Consequence of the Medicare Modernization Act and Free-market Forces?
Oncology has a drug shortage problem, and the FDA says that it is getting worse. Drug shortages are not a new phenomenon, but over the past few years we have seen a rapidly growing number of shortfalls that are limiting providers’ ability to care for their patients. In 2004, the FDA reported 58...
